Nitroso

Advisory - Muscle-relaxant OrfenAce 100 mg tablets recalled because of nitrosamine impurity

Retrieved on: 
Friday, April 16, 2021

b"Issue:SteriMax Inc. is recalling this product because of a nitrosamine impurity.\nWhat to do:You should seek an alternative muscle relaxant to relieve your muscle spasms.

Key Points: 
  • b"Issue:SteriMax Inc. is recalling this product because of a nitrosamine impurity.\nWhat to do:You should seek an alternative muscle relaxant to relieve your muscle spasms.
  • Talk to your health care provider if you have taken a recalled product and have concerns about your health.\nSteriMax Inc. is recalling OrfenAce 100 mg tablets after testing identified a nitrosamine impurity above what is considered acceptable if the drug were to be taken over a lifetime.
  • OrfenAce (a brand name for orphenadrine citrate) is an over-the-counter muscle relaxant used to relieve muscle spasms.\nThe nitrosamine impurity found in OrfenAce is called NMOA (N-methyl-N-nitroso-2-[(2 methylphenyl) phenylmethoxy]ethanamine).
  • Health Canada does not expect that a nitrosamine impurity will cause harm when exposure is at or below the acceptable level.

Nitrosyl Chloride (CAS 2696-92-6) Market Research Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 13, 2019

The "Nitrosyl chloride (CAS 2696-92-6) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nitrosyl chloride (CAS 2696-92-6) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.
  • This Global Report 2019 is a result of industry experts' diligent work on Researching the world market of Nitrosyl chloride.
  • The report helps to build up a clear view of the market (trends and prospects), identify major players in the industry, and estimate main downstream sectors.
  • The Nitrosyl chloride global market Report 2019 key points:

Nitrosyl Chloride (CAS 2696-92-6) Market Report 2019 - Applications, Manufacturing Methods, Patents, Prices & End-Use Sectors

Retrieved on: 
Tuesday, June 11, 2019

DUBLIN, June 11, 2019 /PRNewswire/ -- The "Nitrosyl chloride (CAS 2696-92-6) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 11, 2019 /PRNewswire/ -- The "Nitrosyl chloride (CAS 2696-92-6) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.
  • This Global Report 2019 is a result of industry experts' diligent work on Researching the world market of Nitrosyl chloride.
  • The report helps to build up a clear view of the market (trends and prospects), identify major players in the industry, and estimate main downstream sectors.
  • The Nitrosyl chloride global market Report 2019 key points:

Information Update - Pro Doc Limitée voluntarily recalls two lots of irbesartan drugs because of nitrosamine impurity

Retrieved on: 
Wednesday, March 13, 2019

OTTAWA, March 13, 2019 /CNW/ - Health Canada is advising Canadians that Pro Doc Limiteis voluntarily recalling two lots of irbesartan tablets because of a nitrosamine impurity, N-nitrosodiethylamine (NDEA).

Key Points: 
  • OTTAWA, March 13, 2019 /CNW/ - Health Canada is advising Canadians that Pro Doc Limiteis voluntarily recalling two lots of irbesartan tablets because of a nitrosamine impurity, N-nitrosodiethylamine (NDEA).
  • NDEA is classified as a probable human carcinogen, which means that long-term exposure could increase the potential risk of cancer.
  • Pro Doc Limite is conducting the recall after testing identified levels of NDEA above what is considered reasonably safe if the drug were taken over a lifetime.
  • Health Canada maintains a complete list of sartan drugs that have been recalled because of nitrosamine impurities on its website .